The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial - Tang, Lin-Quan; Li, Xiao-Yun; Li, Zhi-Ming; Liu, Zhi-Gang; Lin, Miao-Zhen; Zhou, Huan; Yu, Qi-Wen; Zhou, Jian; Zhao, Chong; Chen, Ze-Bin; Wang, Xi-Cheng; Peng, Jia-Yu; et al. (BMC medicine, 2023)
Keywords: Anemia; Apatinib; Apoptosis; Cancer; Cancer therapies; Capecitabine; Capecitabine - adverse effects; Chemotherapy; Clinical trials; Disease control; Dosage and administration; Drug dosages; Drug therapy; Drug withdrawal; Effectiveness; Enrollments; Evaluation; Head & neck cancer; Humans; Hypertension; Kinases; Magnetic resonance imaging; Medical prognosis; Metastases; Metastasis; Methods; Mucositis; Nasopharyngeal cancer; Nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Neoplasms - drug therapy; Platinum; Prospective Studies; Protein-tyrosine kinase; Proteinuria; Radiation therapy; Relapse; Safety; Solid tumors; Survival; Throat cancer; Toxicity; Tumors; Tyrosine; Tyrosine kinase inhibitor; Vascular endothelial growth factor; China; Apatinib; Nasopharyngeal carcinoma; Tyrosine kinase inhibitor